Pharmacyclics
Ashish Thakur is a Senior Scientist II at Pharmacyclics, an AbbVie Company, since August 2021. Prior to this role, Ashish worked as a Research Scientist in Medicinal Chemistry at the National Center for Advancing Translational Sciences from July 2015 to August 2021. Ashish's academic background includes a Doctor of Philosophy (Ph.D.) in Organic Chemistry from the University of Utah, earned between 2009 and 2014, and a Master of Science (MSc) in Chemistry from Panjab University, completed in 2008. Ashish also gained research experience as a Graduate Research Assistant at the University of Utah from August 2009 to April 2015 and has a foundational education in Chemistry from Panjab University, where studies were conducted from July 2006 to May 2008.
This person is not in any teams
This person is not in any offices
Pharmacyclics
1 followers
Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer. More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.